- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy. ... Read More
Multiple myeloma and its treatment are frequently characterized by recurrent relapses and shorter remissions1
Representative disease trajectory of multiple myeloma1
For your patients with multiple myeloma, your choice of treatment at first relapse can impact their chance of survival2,3
In 4 out of 10 patients, their treatment at first relapse may be their last2
Of the 40% who do not receive subsequent treatment:
- 30% die
- 40% enter hospice
- 30% refuse further treatment
Data analyzed from the US Census Bureau; National Program of Cancer Registries (NPCR); Surveillance, Epidemiology, and End Results (SEER); and additional primary and secondary research sources.
In patients who receive treatment for subsequent relapses, response rates decline by almost HALF by the third relapse3
The proportion of patients achieving VGPR decreased from 58% at first relapse, to 43% at second relapse, to 32% at third relapse.
VGPR = very good partial response.